Company intelligence / Profile preview
Kite
Santa Monica, California, United Stateskitepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Kite is a leader in commercial autologous CAR-T cell therapies, with Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) approved for various lymphomas and leukemia. Clinical trials show high response rates in relapsed or refractory large B-cell lymphoma (e.g., complete response rate of 78% for KITE-363 in Phase 1a), with a broad global presence and positive long-term results in durability, survival, and real-world studies. Manufacturing process improvements have reduced turnaround time, enabling faster patient access.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
National Cancer InstituteArcellx
Beyond the preview
Go deeper on Kite.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kite.